Jingwen Wang
Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
ITK-targeted immune remodeling enhanced the efficacy of anti-CD19 CAR-T cell therapy.
Journal: Cell death discovery
Published: October 19, 2025
Clinical outcomes and therapeutic modalities in older Chinese patients with MCL: a multi-center real-world retrospective study.
Journal: Annals of medicine
Published: March 28, 2025
Multifunctional ZnO@DOX/ICG-LMHP Nanoparticles for Synergistic Multimodal Antitumor Activity.
Journal: Journal of functional biomaterials
Published: December 15, 2023
PROTAC for Bruton's tyrosine kinase degradation alleviates inflammation in autoimmune diseases.
Journal: Cell discovery
Published: September 26, 2023
Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study.
Journal: Frontiers in immunology
Published: December 20, 2022
The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study.
Journal: Cancer biology & medicine
Published: March 23, 2021
Combined prednisone and levothyroxine improve treatment of severe thrombocytopenia in hepatitis B with compensatory cirrhosis accompanied by subclinical and overt hypothyroidism.
Journal: Science China. Life sciences
Published: July 01, 2017
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Journal: Journal of hematology & oncology
Published: January 16, 2017
Clinical significance of peripheral blood CD4+CD25+ regulatory T cell in patients with extranodal NK/T cell lymphoma, nasal type
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: September 24, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026